Results 51 to 60 of about 199,785 (356)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Vaccines, 2023
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal   +10 more
doaj   +1 more source

In vivo analysis of staphylococcus aureus-infected mice reveals differential temporal and spatial expression patterns of fhuD2 [PDF]

, 2017
Staphylococcus aureus is an opportunistic human pathogen and a major cause of invasive infections such as bacteremia, endocarditis, pneumonia and wound infections.
Bacconi, Marta, Bagnoli, Fabio, Bensi, Giuliano, Chiarot, Emiliano, Delany, Isabel, Donato, Paolo, Freitag, Nancy E., Haag, Andreas F.   +7 more
core   +1 more source

mRNA vaccines for cancer immunotherapy

Frontiers in Immunology, 2022
Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA vaccines are an attractive and powerful immunotherapeutic platform against cancer because of their high potency, specificity, versatility, rapid and large-scale development capability, low-cost manufacturing potential, and safety.
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan, Nikolay V. Dokholyan, Nikolay V. Dokholyan, Nikolay V. Dokholyan   +4 more
openaire   +3 more sources

mRNA vaccine for cancer immunotherapy [PDF]

Molecular Cancer, 2021
AbstractmRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation.
Lei Miao, Yu Zhang, Leaf Huang
openaire   +3 more sources

Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia

Immunity, Inflammation and Disease, 2023
Background and Objectives Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study
Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Abdul Raafe Atif, Muhammad Sohaib Asghar, Nayef Nimri, Maryam Saleem, Dhrubajyoti Bandyopadhyay, Chayakrit Krittanawong, Mohammed Mahmmoud Fadelallah Eljack, Muhammad Junaid Tahir, Fahad Waqar   +12 more
doaj   +1 more source

Deletion of parasite immune modulatory sequences combined with immune activating signals enhances vaccine mediated protection against filarial nematodes [PDF]

, 2012
<p>Background: Filarial nematodes are tissue-dwelling parasites that can be killed by Th2-driven immune effectors, but that have evolved to withstand immune attack and establish chronic infections by suppressing host immunity. As a consequence, the
AB Fredriksen, AB Pedersen, AE O'Connell, AE Schwab, B de Andres, B Manoury, BL Makepeace, BW Li, C Klotz, C Martin, C Martin, D Abraham, D Abraham, D Horst, D Knox, David W. Taylor, DH Barouch, DL Redmond, E Maraskovsky, G Ahlen, G Nchinda, GT Joseph, HA Farid, HongLin Luo, J Gardon, J Murray, JE Allen, JE Allen, JJ Donnelly, JP Hewitson, Judith E. Allen, KJ Fairlie-Clarke, KJ Ishii, LM Mir, LM Mir, LvG Jørgensen, MD Taylor, MD Taylor, MY Osei-Atweneboana, N Gomez-Escobar, Nick Gray, O Golden, PJ Hotez, R Ihaka, RM Maizels, RT Rwegoshora, S Babayan, S Frontier, S Mendez, S Ramachandran, S Thirugnanam, SA Babayan, SA Babayan, SB Anand, SB Anand, SB Anand, Simon A. Babayan, SM Sumida, Stephen John Davies, W Harnett, WF Gregory, WF Gregory, Y Dash, Y Wu   +63 more
core   +4 more sources

Formulation development of a stable influenza recombinant neuraminidase vaccine candidate

Human Vaccines & Immunotherapeutics
Current influenza vaccines could be augmented by including recombinant neuraminidase (rNA) protein antigen to broaden protective immunity and improve efficacy.
Bing Li, Irina V. Ustyugova, Lisa Szymkowicz, Shaolong Zhu, Marin Ming, Karen Y. Y. Fung, Guadalupe Cortés, D. Andrew James, Michael Hrynyk, Nausheen Rahman, Roger H. Brookes, Salvador F. Ausar   +11 more
doaj   +1 more source

Variant constraint by mRNA vaccines [PDF]

Nature Reviews Immunology, 2021
The currently licensed mRNA vaccines for SARS-CoV-2 can elicit cross-neutralizing antibodies against B.1.351 variants of the virus, but are less potent against these variants.
openaire   +2 more sources

Biodistribution of mRNA COVID-19 vaccines in human breast milkResearch in context

EBioMedicine, 2023
Summary: Background: COVID-19 mRNA vaccines play a vital role in the fight against SARS-CoV-2 infection. However, lactating women have been largely excluded from most vaccine clinical trials.
Nazeeh Hanna, Claudia Manzano De Mejia, Ari Heffes-Doon, Xinhua Lin, Bishoy Botros, Ellen Gurzenda, Christie Clauss-Pascarelli, Amrita Nayak   +7 more
doaj   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources